The HuGEMM PD-1 mouse model is a chimeric tumor model where the mouse immune system is functional and the PD-1 receptors have been humanized for a more translational immune response.
The PD-1 model was developed by knocking-in human exon 2 to replace its mouse counterpart, which allows the receptor to be recognized by therapeutic antibodies of interest. This enables the ability to test the therapeutic efficacy directly in the mouse model.
PD-1 plays an important role in the immune response, down-regulating the immune system and suppressing T cell inflammatory activity.
Figure 1 (data generated by Nanjing Galaxy Biopharmaceutical Co. Ltd): The chimeric h/mPD-1 protein binds in vitro to both mouse and human PD-L1 as efficiently as the human PD-1 receptor (upper panel). The chimeric protein is also recognized by anti-human PD-1 antibodies (lower panel), which disrupts the PD-1/PD-L1 interaction
Figure 1 (data generated by Nanjing Galaxy Biopharmaceutical Co. Ltd): The chimeric h/mPD-1 protein binds in vitro to both mouse and human PD-L1 as efficiently as the human PD-1 receptor (upper panel). The chimeric protein is also recognized by anti-human PD-1 antibodies (lower panel), which disrupts the PD-1/PD-L1 interaction
Figure 2: Validation of HuGEMM PD-1 with an analog of Opdivo®. Dose dependent inhibition of subcutaneous MC38 tumor growth is observed following treatment with the anti-hPD-1 antibody.
Figure 2: Validation of HuGEMM PD-1 with an analog of Opdivo®. Dose dependent inhibition of subcutaneous MC38 tumor growth is observed following treatment with the anti-hPD-1 antibody.
